<DOC>
	<DOCNO>NCT02941705</DOCNO>
	<brief_summary>Perform randomize , double blind , placebo-controlled Phase 2a feasibility study determine whether treatment HFPEF patient intracoronary allogeneic CDCs affect clinical functional status ( QOL score ) , exercise tolerance ( 6MHW ) , exercise hemodynamics ( supine exercise ergometry right heart catheterization ) , myocardial interstitial fibrosis ( MRI native T1 mapping calculation extracellular volume [ ECV ] gadolinium administration ) , macroscopic fibrosis delay gadolinium enhancement ( DGE ) , diastolic function ( catheterization , echocardiography , BNP ) . Treatment patient symptomatic hypertensive heart disease-induced HFPEF allogeneic CDCs safe improve clinical functional status , exercise tolerance/hemodynamics , myocardial interstitial structure , diastolic function ; mechanism underlying improvement reflect change plasma biomarkers indicate reduction pro-inflammatory pro-fibrotic signaling .</brief_summary>
	<brief_title>Regression-Heart Failure With Preserved Ejection Fraction ( HFpEF )</brief_title>
	<detailed_description>Heart failure preserve ejection fraction ( HFPEF ) distinct clinical heart failure syndrome represent critical unmet need cardiovascular medicine . HFPEF patient mark increase morbidity mortality profound clinical disability . However , date , management strategy demonstrate decrease morbidity mortality decrease clinical disability suffer HFPEF patients.Investigators postulate one pivotal reason previous randomize clinical study fail show efficacy HFPEF trials center around incomplete understand pathophysiologic mechanism underlie development HFPEF . Studies Veteran patient HFPEF relevant animal model HFPEF demonstrate one critical mechanism contribute HFPEF change cardiac interstitium extracellular matrix ( ECM ) fibrillar collagen homeostasis . Preliminary study present application demonstrate highly novel application stem cell therapy rodent model HFPEF result regression ECM fibrosis reversal LV diastolic dysfunction . These preliminary study form foundation 3 specific aim propose application target HFPEF Veterans . The primary secondary objective study determine safety profile CAP-1002 administer intracoronary infusion patient Heart Failure Preserved Ejection Fraction ( HFPEF ) ass exploratory efficacy endpoint determine whether treatment HFPEF patient intracoronary allogeneic CDCs affect clinical functional status ( QOL score ) , exercise tolerance ( 6 Minute Walk Test - 6MWT ) , exercise hemodynamics ( supine exercise ergometry right heart catheterization ) , myocardial interstitial fibrosis ( MRI native T1 mapping calculation extracellular volume [ ECV ] gadolinium administration ) , macroscopic fibrosis delay gadolinium enhancement ( DGE ) , diastolic function ( catheterization , echocardiography , BNP ) . If patient fulfills inclusion criterion clinical HF , preserve EF , increase BNP , increase LA size none exclusion criterion ( see detail ) , consent undergo CT coronary angiography ( define coronary anatomy ) HLA/ donor-specific antibody ( DSA ) screen . If significant CAD identify CT confirm subsequent coronary arteriography FFR , subject referred physician consideration revascularization procedure . If subject undergo revascularization procedure , subject may reconsider rescreened study , minus repeat CT , minimum 3 month post-revascularization . Capricor generate various Master Cell Banks ( MCBs ) transplant-quality donor heart distinct HLA profile . The HLA/DSA screen perform Capricor use select appropriate MCB CAP-1002 specific patient , goal avoid MCBs antigens subject may pre-sensitized gauged presence circulate DSA single-antigen bead serum antibody profile . In company 's experience , cross-matching &gt; 100 subject ALLSTAR DYNAMIC trial , appropriate non-reactive CAP-1002 MCB source &gt; 90 % case . All patient CAP-1002 placebo deliver coronary catheter insert right left coronary artery use standard technique cardiac catheterization laboratory . A right heart catheter use obtain baseline ( pre-infusion ) hemodynamics . All patient receive 25 million cell ( CAP-1002 ) placebo 3 coronary artery . Sequential dose administration 25 million cell suspend in10 mL cryopreservation solution ( CryoStor® CS10 , BioLife Solutions , Inc. ) contain 10 % dimethyl sulfoxide ( DMSO ) , 1800 unit heparin 45 mcg nitro deliver via coronary artery catheter . Additionally , four milliliter intermediate wash solution contain saline also administer patient . Patients randomized placebo group receive placebo injection consist CAP-1002 minus active CDC constituent . Each 10ml bag 25 million cell infused 1 ml/min . All procedure perform cardiac interventionist ( Dr Fernandes ) . The patient receive local anesthesia +/- gentle conscious sedation undue anxiety . During infusion , multiple measure gas exchange , hemodynamics , include blood pressure heart rate monitoring arrhythmia ( ventricular supra-ventricular ) . Fluids permit hypotension procedure , low dose inotropes dobutamine use inhale nitric oxide . VPCs NSVT see insertion PA catheter traverse RV easily remedied catheter withdrawal . Oxygen used patient already O2 therapy baseline need treat temporary hypoxia occur . If significant adverse event occur , cell infusion terminate . Pre-specified infusion related event include follow within 6 hour CDC infusion : refractory hypotension require pressor inotropes , significant hypoxemia require FiO2 &gt; 0.4 increment &gt; 0.2 baseline , new cardiac arrhythmia require cardioversion , ventricular tachycardia , ventricular fibrillation , asystole pulseless electrical activity , acute severe transfusion reaction ( immune infection relate ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<criteria>1 . ≥ 50 year old , male female 2 . LVEF ≥ 50 % 3 . Symptoms physical finding chronic heart failure ( NYHA class II ambulatory IV ) 4 . Treatment diuretic ( ) least 30 day prior randomization . 5 . Left atrial ( LA ) enlargement define least one following : LA width ( diameter ) ≥ 3.8 cm LA length ≥ 5.0 cm LA area ≥ 20 cm2 LA volume ≥ 55 mL LA volume index ≥ 29 mL/m2 6 . BNP &gt; 125 pg/ml patient NSR &gt; 150 pg/ml patient AF Exclusion criteriaSpecific HFPEF 1 . Any prior echocardiographic measurement LVEF &lt; 40 % 2 . Acute coronary syndrome ( include MI ) , cardiac surgery , major CV surgery , percutaneous coronary intervention ( PCI ) within 3 month prior randomization 3 . Unrevascularized , hemodynamically significant CAD ( FFR &lt; 0.75 ) 4 . Current acute decompensated HF 5 . Alternative diagnosis opinion investigator could account patient 's HF symptom ( i.e. , dyspnea , fatigue ) severe pulmonary disease ( i.e. , require home oxygen , chronic nebulizer therapy , chronic oral steroid therapy ) ; hemoglobin ( Hgb ) &lt; 10 g/dl ; body mass index ( BMI ) &gt; 40 kg/m2 6 . Use investigational drug treatment time enrollment 7 . Systolic blood pressure &gt; 150 mmHg &lt; 180 mmHg unless receive 3 antihypertensive drug 8 . History dilate cardiomyopathy ; right side HF absence leftsided structural heart disease ; Pericardial constriction , genetic hypertrophic cardiomyopathy , infiltrative cardiomyopathy ; clinically significant congenital heart disease ; hemodynamically significant valvular heart disease 9 . Stroke , transient ischemic attack , carotid surgery carotid angioplasty within 3 month 10 . Uncontrolled dysrhythmia ; symptomatic sustain ventricular tachycardia atrial fibrillation flutter rest ventricular rate &gt; 110 beat per minute ( bpm ) 11 . Prior major organ transplant intent transplant ( i.e. , transplant list ) 12 . Hepatic disease determine one following : SGOT ( AST ) SGPT ( ALT ) value exceed 3x upper limit normal ( ULN ) , bilirubin &gt; 1.5 mg/dl ; history chronic viral hepatitis 13 . Chronic Kidney Disease eGFR &lt; 30 mL/min/1.73 m2 ; serum potassium &gt; 5.5 mmol/L ( mEq/L ) 14 . History presence disease life expectancy &lt; 3 year 15 . Noncompliance medical regimen 16 . Drug alcohol abuse within last 12 month 17 . History malignancy within past 5 year 18 . Pregnant nursing ( lactate ) woman confirm positive human chorionic gonadotropin ( hCG ) ; woman childbearing potential ( physiologically capable become pregnant ) , unless use highly effective contraception method study Exclusion criteriaSpecific CAP1002 ( list ) 1 . Diagnosis active myocarditis 2 . Immunologic incompatibility available CAP1002 MCBs singleantigen bead ( SAB ) serum antibody profile 3 . Known hypersensitivity contrast agent 4 . Active infection responsive treatment 5 . Active allergic reaction , connective tissue disease autoimmune disorder 6 . History cardiac tumor cardiac tumor demonstrate screen 7 . History previous stem cell therapy 8 . History treatment immunosuppressive agent , include chronic systemic corticosteroid , biologic agent target immune system , antitumor antineoplastic drug antiVEGF within 6 month prior enrollment ( include drugeluting coronary stent ) 9 . Human Immunodeficiency Virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>stem cell research</keyword>
</DOC>